{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:46:09Z","timestamp":1790027169944,"version":"4.0.1"},"reference-count":31,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The primary objective of this work was to assess the prevalence and distribution of HPV genotypes in immunosuppressed patients, and to compare them with the French Monsonego cohort. Secondary objectives were to evaluate whether the risk of HPV infection was correlated with HIV viral load, CD4 cell count in HIV-infected patients and the type, number of immunosuppressive therapies or type of pathology (transplant vs. autoimmune diseases) in patients undergoing long-term immunosuppressive therapy. Methods: An observational, monocentric and historical study was conducted including all immunosuppressed patients having received an HPV testing, in the Laboratory of Virology, Nancy Regional Teaching Hospital Center, between 2014 and 2020. Immunosuppressed patients were either HIV-infected or received long-term immunosuppressive therapy. Results: In our cohort, the prevalence of HPV infection (75.6% vs. 16.1% p &lt; 0.05), the proportion of patients with high-risk HPV infection (48.9% vs. 15.1% p &lt; 0.05) and with multiple HPV infection (41.1% vs. 5.7% p &lt; 0.05) were significantly higher than in the Monsonego cohort. HPV 52 (13%), 53 (13%) and 16 (10%) were the most common in the immunosuppressed population, while it was HPV 16, 42 and 51 in the Monsonego cohort. Conclusions: This study supports that a particular attention must be given to all the immunosuppressed patients for the screening and care of HPV-related diseases because of major modifications of HPV epidemiology compared with the overall population.<\/jats:p>","DOI":"10.3390\/v13122454","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T20:23:21Z","timestamp":1638908601000},"page":"2454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3100-3688","authenticated-orcid":false,"given":"Margot","family":"Boudes","sequence":"first","affiliation":[{"name":"Department of Medical Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, France"},{"name":"Faculty of Medicine, University of Lorraine, 9 Avenue de la For\u00eat de Haye, 54505 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-7887","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Venard","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Lorraine, 9 Avenue de la For\u00eat de Haye, 54505 Nancy, France"},{"name":"Laboratory of Virology, CHRU Nancy, 54505 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Routiot","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Buzzi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Lorraine, 9 Avenue de la For\u00eat de Haye, 54505 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Maillot","sequence":"additional","affiliation":[{"name":"Department of Medical Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, France"},{"name":"Faculty of Medicine, University of Lorraine, 9 Avenue de la For\u00eat de Haye, 54505 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"ref_1","unstructured":"(2021, August 04). Le VIH\/Sida en France en 2018. Available online: https:\/\/vih.org\/dossier\/le-vih-sida-en-france-en-2018\/."},{"key":"ref_2","unstructured":"(2021, August 21). L\u2019activit\u00e9 de Greffe d\u2019organes Repart \u00e0 la Hausse en 2019\u2014Agence de la biom\u00e9Decine. Available online: https:\/\/www.agence-biomedecine.fr\/L-activite-de-greffe-d-organes-repart-a-la-hausse-en-2019-1295."},{"key":"ref_3","unstructured":"(2021, August 21). Liste des Maladies Auto-Immunes\u2014CRMR des Maladies Auto-Immunes de Strasbourg (RESO). Available online: https:\/\/maladie-autoimmune.fr\/maladies-auto-immunes\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/jcm4020260","article-title":"HPV Carcinomas in Immunocompromised Patients","volume":"4","author":"Reusser","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_5","first-page":"521","article-title":"Frequency, persistence and recurrence of HPV lesions of the uterine cervix in HIV-seropositive women","volume":"36","author":"Badiou","year":"2008","journal-title":"Gynecol. Obstet. Fertil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: From basic studies to clinical application","volume":"2","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAI.0b013e31828177d7","article-title":"Invasive cervical cancer risk among HIV-infected women: A North American multicohort collaboration prospective study","volume":"62","author":"Abraham","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.critrevonc.2012.02.008","article-title":"HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients","volume":"84","author":"Hinten","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1477-7819-9-72","article-title":"Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients","volume":"9","author":"Park","year":"2011","journal-title":"World J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1002\/art.20616","article-title":"Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection","volume":"50","author":"Tam","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at increased risk of cervical high-grade dysplasia\/cancer? A Meta-Analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2036.2008.03766.x","article-title":"Screening differences and risk of cervical cancer in inflammatory bowel disease","volume":"28","author":"Hutfless","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"354.e1","DOI":"10.1016\/j.ajog.2015.09.086","article-title":"Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women","volume":"214","author":"Massad","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/QAD.0000000000001765","article-title":"HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer","volume":"32","author":"Liu","year":"2018","journal-title":"AIDS Lond. Engl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.vaccine.2013.12.060","article-title":"Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India","volume":"32","author":"Joshi","year":"2014","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/QAI.0000000000001113","article-title":"Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa","volume":"73","author":"Clifford","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/ajt.13053","article-title":"Cervicovaginal HPV infection in female renal transplant recipients: An observational, self-sampling based, cohort study","volume":"15","author":"Meeuwis","year":"2015","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/aogs.13261","article-title":"Cervical HPV prevalence and genotype distribution in immunosuppressed Danish women","volume":"97","author":"Roensbo","year":"2018","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gyobfe.2013.03.003","article-title":"Pr\u00e9valence des g\u00e9notypes d\u2019HPV chez les femmes en France: Implications pour le d\u00e9pistage et la vaccination","volume":"41","author":"Monsonego","year":"2013","journal-title":"Gyn\u00e9cologie Obst\u00e9trique Fertil."},{"key":"ref_22","first-page":"313","article-title":"Distribution des g\u00e9notypes de papillomavirus humain (HPV) dans les l\u00e9sions g\u00e9nitales en France: \u00c9tude EDITH","volume":"29","author":"Jacquard","year":"2009","journal-title":"BEH"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wielgos, A., Pietrzak, B., Sikora, M., Martirosian, G., Suchonska, B., Gozdowska, J., Oldakowska-Jedynak, U., Jabiry-Zieniewicz, Z., Durlik, M., and Rudnicka, L. (2020). Human Papillomavirus (HPV) DNA Detection Using Self-Sampling Devices in Women Undergoing Long Term Immunosuppressive Therapy. Viruses, 12.","DOI":"10.3390\/v12090962"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1002\/ijc.29209","article-title":"Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: Population-based cohort study","volume":"136","author":"Rebolj","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0961203311425517","article-title":"Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis","volume":"21","author":"Trujillo","year":"2012","journal-title":"Lupus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/0961203316672928","article-title":"Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus Receiving Immunosuppressive Drugs","volume":"26","author":"Feldman","year":"2017","journal-title":"Lupus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1023\/A:1020668232219","article-title":"Clearance of oncogenic human papillomavirus (HPV) infection: Effect of smoking (United States)","volume":"13","author":"Giuliano","year":"2002","journal-title":"Cancer Causes Control"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-1702(02)00188-0","article-title":"Environmental co-factors in HPV carcinogenesis","volume":"89","author":"Bosch","year":"2002","journal-title":"Virus Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.2014.13183","article-title":"Tobacco use and oral HPV16 infection","volume":"312","author":"Fakhry","year":"2014","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2016.06.049","article-title":"Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children","volume":"34","author":"MacIntyre","year":"2016","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1016\/j.vaccine.2019.07.072","article-title":"Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children","volume":"37","author":"MacIntyre","year":"2019","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:21Z","timestamp":1760168541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["v13122454"],"URL":"https:\/\/doi.org\/10.3390\/v13122454","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]}}}